Black Diamond Therapeutics, Inc. – NASDAQ:BDTX

Add to watchlist

$2.64

+0.45

+20.55%

Market closed

Open in about 7 hours

-61.24%

month

-61.24%

quarter

-26.26%

year

Market Cap	120.57M
Enterprise value	46.19M

P/E	-0.66
EV/Sales	N/A
EV/EBITDA	36.55
Price/Sales	N/A
Price/Book	0.47
PEG ratio	N/A
EPS	-1.7

Revenue	N/A
EBITDA	-84.85M
Income	-79.79M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Profit margin
Jun 2023	0	-19.15M
Sep 2023	0	-23.00M
Dec 2023	4.89M	-19.40M	-396.57%
Mar 2024	0	-18.22M

Black Diamond Therapeutics Financials Estimate

Q Y

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Analyst Estimates
Mar 2024	0	-18.22M
Sep 2025	0	-23.81M
Oct 2025	0	-24.65M
Dec 2025	0	-25.02M

Analysts Price target
Financials & Ratios estimates

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Debt to assets
Jun 2023	119879000	37.68M	31.43%
Sep 2023	172382000	38.06M	22.08%
Dec 2023	158567000	41.83M	26.38%
Mar 2024	142521000	38.21M	26.81%

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Cash Flow
Jun 2023	-14.36M	17.17M	0
Sep 2023	-18.36M	-37.88M	71.92M
Dec 2023	-13.95M	12.24M	-46K
Mar 2024	-21.19M	-13.73M	4.13M

Black Diamond Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Black Diamond Therapeutics
Employees

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Employee count
Aug 2023	65
Sep 2023	65
Oct 2023	65
Nov 2023	65
Dec 2023	65
Jan 2024	65
Feb 2024	65
Mar 2024	54
Apr 2024	54
May 2024	54
Jun 2024	54
Jul 2024	54

Black Diamond Therapeutics
Hedge Funds Holdings Q1 2023

8.77% -49.16%

of BDTX is owned by hedge funds

26 -29

hedge funds hold BDTX stock

3.18M -17.86M

shares is hold by hedge funds

BDTX hedge funds holdings changes

Black Diamond Therapeutics
Insider Trading

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	400000	0
Aug 2024	0	221600

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	28 Aug 2024	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	221,600	$6.32	$1,400,512
Purchase	17 Oct 2023	BIOTECH GROWTH N V 10 percent owner 10 percent owner	Common Stock	400,000	$2.34	$934,000
Purchase	5 Jul 2023	RA CAPITAL MANAGEMENT, L.P. director director	Common Stock	935,850	$5	$4,679,250
Purchase	5 Jul 2023	BEHBAHANI ALI director director	Common Stock	1,000,000	$5	$5,000,000
Purchase	30 Jun 2023	BIOTECH GROWTH N V 10 percent owner 10 percent owner	Common Stock	1,000,000	$5	$5,000,000
Purchase	27 Jun 2023	BIOTECH GROWTH N V 10 percent owner 10 percent owner	Common Stock	1,740,000	$5.49	$9,554,340
Sale	27 Jun 2023	EPSTEIN DAVID M. director, officer..	Common Stock	25,000	$6.7	$167,500
Purchase	22 Dec 2022	NI FANG officer: SEE REMARKS officer: SEE REMARKS	Common Stock	36,363	$1.28	$46,581
Purchase	21 Dec 2022	NI FANG officer: SEE REMARKS officer: SEE REMARKS	Common Stock	20,000	$1.29	$25,780
Purchase	31 Oct 2022	BIOTECH GROWTH N V 10 percent owner 10 percent owner	Common Stock	99,801	$2.25	$224,951

BDTX insider trading transactions

Black Diamond Therapeutics
Patents

Status	Patent	Filling date	Issue date
Application	Application TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE Filling date: 24 Sep 2019 Issue date: 10 Feb 2022	24 Sep 2019	10 Feb 2022
Application	Application TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE Filling date: 17 Apr 2020 Issue date: 3 Jun 2021	17 Apr 2020	3 Jun 2021

BDTX patents

Black Diamond Therapeutics
Executives

Insider	Age	Compensation
Dr. David M. Epstein (1959) Co-Founder, Pres, Chief Executive Officer & Director	66	$837,790
Mr. Brent Hatzis-Schoch Esq., J.D. (1965) Chief Operating Officer & Gen. Counsel	60	$670,230
Dr. Rachel Wallach Humphrey M.D., Ph.D. (1961) Advisor	64	$228,890

Black Diamond Therapeutics
Latest News

Wednesday, 11 December 2024
13:01	Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know	zacks.com
Tuesday, 5 November 2024
08:00	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Friday, 1 November 2024
08:00	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Tuesday, 8 October 2024
15:24	Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data	seekingalpha.com
Monday, 7 October 2024
16:01	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway	globenewswire.com
Monday, 23 September 2024
07:00	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations	globenewswire.com
Sunday, 22 September 2024
10:00	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC	globenewswire.com
Saturday, 14 September 2024
03:30	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024	globenewswire.com
Thursday, 8 August 2024
13:01	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy	zacks.com
Tuesday, 6 August 2024
07:30	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Saturday, 1 June 2024
10:00	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Wednesday, 29 May 2024
08:00	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference	globenewswire.com
Friday, 10 May 2024
09:51	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?	Zacks Investment Research
Monday, 29 April 2024
09:51	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable	Zacks Investment Research
Thursday, 25 April 2024
10:56	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?	Zacks Investment Research
Monday, 15 April 2024
13:01	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?	Zacks Investment Research
Monday, 8 April 2024
10:56	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know	Zacks Investment Research
Friday, 22 March 2024
10:55	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%	Zacks Investment Research
Friday, 12 January 2024
17:21	Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM	Seeking Alpha
Tuesday, 7 November 2023
08:00	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 4 October 2023
12:14	Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	GlobeNewsWire
Tuesday, 5 September 2023
08:00	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Thursday, 29 June 2023
17:48	Why Shares of Black Diamond Therapeutics Skyrocketed This Week	The Motley Fool
Tuesday, 27 June 2023
11:56	Black Diamond Therapeutics stock rockets after positive trial data shows anti-tumor activity	Proactive Investors
11:00	Why Is Black Diamond Therapeutics (BDTX) Stock Up 82%?	InvestorPlace
Friday, 2 June 2023
08:00	Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference	GlobeNewsWire
Monday, 27 February 2023
08:00	Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference	GlobeNewsWire
Thursday, 5 January 2023
08:00	Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Friday, 9 December 2022
11:17	Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)	Zacks Investment Research
Wednesday, 9 November 2022
08:00	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Black Diamond Therapeutics stock today?

One share of Black Diamond Therapeutics stock can currently be purchased for approximately $2.64.
When is Black Diamond Therapeutics's next earnings date?

Unfortunately, Black Diamond Therapeutics's (BDTX) next earnings date is currently unknown.
Does Black Diamond Therapeutics pay dividends?

No, Black Diamond Therapeutics does not pay dividends.
How much money does Black Diamond Therapeutics make?

Black Diamond Therapeutics has a market capitalization of 120.57M.
What is Black Diamond Therapeutics's stock symbol?

Black Diamond Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BDTX".
What is Black Diamond Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Black Diamond Therapeutics?

Shares of Black Diamond Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Black Diamond Therapeutics's key executives?
Black Diamond Therapeutics's management team includes the following people:
- Dr. David M. Epstein Co-Founder, Pres, Chief Executive Officer & Director(age: 66, pay: $837,790)
- Mr. Brent Hatzis-Schoch Esq., J.D. Chief Operating Officer & Gen. Counsel(age: 60, pay: $670,230)
- Dr. Rachel Wallach Humphrey M.D., Ph.D. Advisor(age: 64, pay: $228,890)
Is Black Diamond Therapeutics founder-led company?

Yes, Black Diamond Therapeutics is a company led by its founder Dr. David M. Epstein.
How many employees does Black Diamond Therapeutics have?

As Jul 2024, Black Diamond Therapeutics employs 54 workers.
When Black Diamond Therapeutics went public?

Black Diamond Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 31 Jan 2020.
What is Black Diamond Therapeutics's official website?

The official website for Black Diamond Therapeutics is blackdiamondtherapeutics.com.
Where are Black Diamond Therapeutics's headquarters?

Black Diamond Therapeutics is headquartered at One Main Street, Cambridge, MA.
How can i contact Black Diamond Therapeutics?

Black Diamond Therapeutics's mailing address is One Main Street, Cambridge, MA and company can be reached via phone at +61 72520848.

Black Diamond Therapeutics, Inc.

blackdiamondtherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

+61 72520848

One Main Street
Cambridge, MA 02142

CIK: 0001701541
ISIN: US09203E1055
CUSIP: 09203E105